ALX Oncology Holdings Inc. (ALXO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

ALX Oncology Holdings Inc. (ALXO) closed at USD 1.00 on 2026-10-15, a change of -37.1 % over the past year, with a market capitalization of USD 146.57M.

ALX Oncology Holdings Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ALX Oncology Holdings Inc. key figures

Previous close

USD 1.00 (2026-10-15)

1-year change

-37.1 %

Market cap

USD 146.57M

Enterprise value

USD 19.38M

P/E ratio (trailing)

-0.94

P/E ratio (forward)

-1.97

EPS (trailing)

-1.13

EPS (forward)

-0.54

PEG ratio

n/a

Price to book

1.08

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.97

Employees

48

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ALX Oncology Holdings Inc. and compare it with other stocks.